Boston Scientific

IRHYTHM ALERT: Bragar Eagel & Squire, P.C. is Investigating iRhythm Technologies, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm

Retrieved on:

水曜日, 5月 22, 2024

IRTC, Patient, Justice, J. P. Morgan, Heart failure, Subpoena duces tecum, FDA, Telephone, Stroke, Marketing, Growth, ECG, Atrial fibrillation, Zio, P.C, Boston Scientific, DOJ, Medical device

Our investigation concerns whether the board of directors of iRhythm have breached their fiduciary duties to the company.

Key Points:

Our investigation concerns whether the board of directors of iRhythm have breached their fiduciary duties to the company.
The Company’s principal product is a monitoring patch that provides electrocardiogram (“ECG”) monitoring for up to 14 days, called Zio XT.
The Zio XT is intended for non-critical patients, as it does not provide real-time reporting.
As a result of these misrepresentations, the price of iRhythm common stock traded at artificially inflated prices throughout the Class Period.

deepull appoints Didier Deltort to its Board of Directors

Retrieved on:

水曜日, 5月 22, 2024

Sepsis, Patient, HP Inc., Google Images, Senior advisor, Biomedicine, Management, SVP, Marketing, Relevance, Partnership, HP, Boston Scientific, GE HealthCare, Zimmer Biomet, Pharmaceutical industry

Barcelona, Spain – 22 May 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointment of Didier Deltort to its Board of Directors.

Key Points:

Barcelona, Spain – 22 May 2024 – deepull, a medical diagnostics company developing culture-free diagnostic solutions for rapid pathogen identification for sepsis and other acute infections, today announces the appointment of Didier Deltort to its Board of Directors.
Didier has spent over 30 years leading healthcare technology innovation and businesses around the world.
Prior to Zimmer Biomet, Didier was Senior Vice President and General Manager, Global Healthcare Solutions and Partnerships at Boston Scientific.
I look forward to working closely with the Management and the Board as deepull heads towards important clinical and commercial milestones.”

Hyperfine, Inc. to Expand Global Market Reach with Appointment of International Distributors in Key European Markets

Retrieved on:

金曜日, 5月 10, 2024

The system the company is introducing to the European markets is commercialized in the U.S. and is the highest performing Swoop® system to date in terms of image quality and usability.

Key Points:

The system the company is introducing to the European markets is commercialized in the U.S. and is the highest performing Swoop® system to date in terms of image quality and usability.
Introducing the Swoop® system into international markets is a significant step in supporting the commercial growth of Hyperfine, Inc.
The Swoop® system can expand the existing imaging market with its transformative, affordable, and accessible platform to serve more clinicians and patients needing brain imaging.
“There is a growing global demand for accessible MR brain imaging, which the versatile Swoop® system can meet.

James Brodie of Johnson & Johnson MedTech Appointed Chair of the Medtech Canada Board of Directors

Retrieved on:

金曜日, 5月 10, 2024

McMaster University, Marketing, Health care, Pleasure, Johnson & Johnson, Government, Convatec, Medical device, Chairperson, Medication, Fresenius Medical Care, Hospital, Health, Boston Scientific, Roche, Siemens Healthineers, Management

TORONTO, May 10, 2024 /CNW/ - Medtech Canada, the national association representing Canada's medical technology companies, is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors.

Key Points:

TORONTO, May 10, 2024 /CNW/ - Medtech Canada, the national association representing Canada's medical technology companies, is very pleased to welcome James Brodie of Johnson & Johnson MedTech as Chair of the Medtech Canada Board of Directors.
James Brodie is General Manager of Johnson & Johnson MedTech (JJMT) in Canada.
"I'm very honoured to Chair the Medtech Canada Board of Directors and I look forward to working collaboratively with my fellow board members and the Medtech Canada team to enhance the medtech environment in Canada," said Mr. Brodie.
"I've had the pleasure of working closely with James during his tenure on the Medtech Canada board and I know that his leadership and extensive experience will be invaluable as he takes on the role of Board Chair for our association," said Nicole DeKort, President and CEO, Medtech Canada.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on:

木曜日, 5月 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points:

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Electronic Skin Patch Market worth $27.0 billion by 2029 - Exclusive Report by MarketsandMarkets™

Retrieved on:

木曜日, 5月 9, 2024

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.

Key Points:

Connected electronic skin patches in Wireless Connectivity segment is expected to account for the largest share during the forecast period.
Diabetes Management segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Healthcare segment in Electronic Skin Patch Market will account for largest share during the forecast period.
Based on end user, the electronic skin patch market has been categorized into healthcare, fitness & sports, and other end users.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on:

木曜日, 5月 9, 2024

PFA, Physics, Safety, Arrhythmia, Catheter ablation, HRS, PVC, MD, Cardiac electrophysiology, Workflow, Mount Sinai Health System, Ventricular tachycardia, Cardiac cycle, Patient, Atrial fibrillation, Boston Scientific, Medical device

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points:

First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Field Medical Announces First-in-Human Trials for Groundbreaking FieldForce™ Ventricular Pulsed Field Ablation Technology

Retrieved on:

木曜日, 5月 9, 2024

CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic. The Ventricular Catheter Ablation Study, VCAS, will enroll up to 60 patients at up to 5 sites world-wide. The VCAS investigational study is a critical step towards demonstrating safety and performance of the FieldForce™ Ablation System, developed specifically to address the limitations of existing pulsed field ablation (PFA) and radiofrequency (RF) ablation systems, including a more time efficient treatment protocol for the treatment of ventricular arrhythmias. Preliminary results will be presented on May 16, 2024, at the Heart Rhythm Scientific Sessions in Boston, Mass.

Key Points:

First and only contact force pulsed field ablation (PFA) system designed to transform treatment for millions with life-threatening ventricular arrhythmias.
CARDIFF-BY-THE-SEA, Calif., May 9, 2024 /PRNewswire/ -- Field Medical,™ Inc., a pioneer in pulsed field cardiac catheter ablation technology, today announced the initiation of its first-in-human study for the FieldForce™ Ablation System at Na Homolce Hospital in Prague, Czech Republic.
The Ventricular Catheter Ablation Study, VCAS , will enroll up to 60 patients at up to 5 sites world-wide.
Current ventricular catheter ablation methods involve lengthy procedures and significant risks associated with thermal ablation, like conventional RF ablation.

Quaker Houghton Announces CFO Transition

Retrieved on:

木曜日, 5月 9, 2024

Corporate finance, CFO, Polaris Inc., Information technology, CPA, Consumables, KWR, CFA, Chartered Financial Analyst, Boston Scientific, Certified Public Accountant, Growth, Management

CONSHOHOCKEN, Pa., May 9, 2024 /PRNewswire/ -- Quaker Houghton ("the Company"; NYSE: KWR) announced today that it has appointed Tom Coler as Executive Vice President and Chief Financial Officer effective June 10, 2024.

Key Points:

CONSHOHOCKEN, Pa., May 9, 2024 /PRNewswire/ -- Quaker Houghton ("the Company"; NYSE: KWR) announced today that it has appointed Tom Coler as Executive Vice President and Chief Financial Officer effective June 10, 2024.
Mr. Hostetter will remain at the company through August 4, 2024, to ensure an orderly transition.
He has demonstrated success as a CFO as well as in various financial leadership roles at both public and private companies.
While at Quaker Houghton, Shane has improved our strong financial foundation, advanced our strategic initiatives, and helped to further unlock our growth potential.

Boston Scientific Elects Dr. Cheryl Pegus to Board of Directors

Retrieved on:

水曜日, 5月 8, 2024

Brandeis University, Weill Cornell Medicine, Public health, Woman, Health, Johnson & Johnson, Private practice, Cambia Health Solutions, Pfizer, Patient, Boston Scientific, BSX, American Heart Association

MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.

Key Points:

MARLBOROUGH, Mass., May 8, 2024 /PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) announced today the election of Dr. Cheryl Pegus to its board of directors, effective immediately.
Prior to that, Dr. Pegus was executive vice president of Health & Wellness at Walmart, president of Consumer Solutions and chief medical officer for Cambia Health Solutions and chief medical officer at Walgreens.
Dr. Pegus began her career in private practice as a cardiologist and previously served as board chair for the Association of Black Cardiologists.
"We are pleased to expand our board of directors with a highly respected, visionary clinical leader," said Mike Mahoney, chief executive and chairman of the board, Boston Scientific.